GENE ONLINE|News &
Opinion
Blog

2021-07-10| Asia-Pacific

Sparx Therapeutics to Build a Massive Manufacturing Plant in China for Multi-Specific Antibody Production

by Tyler Chen
Share To

Founded just around 3 years ago, a small Chicago biotech is prepared to build a huge production center in the Yangzhou Economic Zone, China, to increase manufacturing capacity for its antibody-drug pipelines.

On July 8th, Sparx Therapeutics announced the plan to establish a 1.2 million-square-foot plant in China and is estimated to begin operating at the end of 2022.

 

Increasing Capacity for Commercial Production

The new plant in China will include a 400,000-square-foot cGMP cleanroom and a total bioreactor capacity of 80,000-liters in separate cleanroom suites. The goal is to produce five commercial products simultaneously and fulfill the needs of chemistry, manufacturing, and controls (CMC) for over 12 programs in clinical trials.

“The planned facilities, with a total bioreactor capacity of 80,000-liters, will provide sufficient quantities of drug substances and drug products to support preclinical and clinical development and ultimately commercial launch”, said Dr. Gui-Dong Zhu, CEO of Sparx.

 

Targeting Solid Tumors with Multi-Specific Antibody

Sparx develops multi-specific antibody and antibody-drug conjugate (ADC) discovery platforms to target solid tumors such as gastric and colon cancer. 

Currently, the firm has three first-in-class candidates in the preclinical stage and three candidates ready for an investigational new drug (IND) application. Its R&D power has also attracted Eli Lilly’s distinguished research fellow, Dr. Victor Wroblewski, to join as the senior VP and the head of biology.

Aside from the expected plant in Yangzhou Economic Zone, Sparx has in-house facilities in Chicago and China to manufacture clinical and commercial drug substances but feels the need to expand as they couldn’t meet the development needs for antibody production, especially commercial use.

Related Article: Gilead’s Yescarta Becomes First CAR-T Therapy to Score Regulatory Approval in China

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
ImmunoGen Wins FDA Accelerated Approval For Ovarian Cancer Drug
2022-11-16
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
WuXi Biologics, Toregem BioPharma To Develop Tooth-Regenerating Antibody
2022-10-14
LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!